Back to search

Article

In Vivo Study of Newly Developed Albumin-Conjugated Urate Oxidase for Gout Treatment

2023-10-24

Abstract excerpt

<h4>Background: </h4> Exogenously providing engineered Uox with enhanced half-life is one of the important urate-lowering treatments for gout. The potential of PAT101, a recombinant human albumin (rHA)-conjugated variant, was evaluated and compared as a novel gout treatment through various in vivo studies with PAT101 and competing drugs. <h4>Methods: </h4>: PAT101 was produced by site-specific conjugation of rHA...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3a8822e1-9cd5-5a76-9547-0f015056fac3
DOI
10.21203/rs.3.rs-3460642/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
In Vivo Study of Newly Developed Albumin-Conjugated Urate Oxidase for Gout TreatmentDOI 10.21203/rs.3.rs-3460642/v1
Select a neighboring publication to make it the new centre.